Tramadol Hydrochloride + ParacetamolThird Party Manufacturing in India

This fixed-dose combination tablet brings together two analgesics with distinct and complementary mechanisms of action to provide effective relief for moderate to moderately severe acute pain. Tramadol hydrochloride is a centrally acting synthetic opioid analgesic that binds with weak affinity to mu-opioid receptors in the central nervous system, while simultaneously inhibiting the reuptake of norepinephrine and serotonin at the synaptic cleft. The plus-enantiomer of tramadol has higher affinity for mu-opioid receptors and preferentially inhibits serotonin reuptake, whereas the minus-enantiomer primarily inhibits norepinephrine reuptake through stimulation of alpha-2 adrenergic receptors. This dual monoaminergic modulation activates descending inhibitory pain pathways in the spinal cord and brainstem, reducing pain signal transmission.

Paracetamol, also known as acetaminophen, provides antipyretic and analgesic activity through a mechanism that is not entirely understood but is believed to involve inhibition of cyclooxygenase enzymes in the central nervous system, particularly COX-3, and activation of descending serotonergic pathways. The combination of tramadol and paracetamol produces synergistic analgesia through their complementary central and peripheral actions. Tramadol primarily modulates pain at the spinal and supraspinal levels, while paracetamol contributes additional analgesic effect through its central COX inhibition and serotonergic activity.

This synergy allows the combination to achieve effective pain relief at lower individual doses of each component, reducing the dose-dependent adverse effects of tramadol such as nausea, dizziness, and constipation. The onset of analgesia occurs within 30 to 60 minutes after oral administration, and the duration of action is approximately 4 to 6 hours, supporting regular dosing intervals for acute pain management.

Therapeutic Uses

Tramadol hydrochloride and paracetamol tablets (37.5 mg + 325 mg) are indicated for the short-term management of acute moderate to severe pain where a combination of opioid and non-opioid analgesics is appropriate.

• Acute Musculoskeletal Pain: The combination is effective for acute back pain, sprains, strains, and other musculoskeletal injuries where moderate to severe pain requires more than simple analgesics alone.
• Postoperative Pain: Tramadol-paracetamol combination is widely used for pain management after surgical procedures, providing effective analgesia with a lower opioid burden than tramadol alone or other stronger opioids.
• Dental Pain: Following dental extractions and oral surgeries, this combination provides effective pain relief with a favorable balance of efficacy and tolerability.
• Acute exacerbations of Chronic Pain: For patients with chronic pain conditions such as osteoarthritis who experience acute pain flares, this combination offers a step-up option from non-opioid analgesics.

Why Manufacturers Choose Tramadol + Paracetamol

Tramadol-paracetamol fixed-dose combination tablets are among the most prescribed analgesic products in India. The 37.5 mg + 325 mg strength is a standardized formulation produced in large volumes by Indian pharmaceutical companies for both the domestic market and international export.

The combination's popularity stems from its proven efficacy, reduced opioid burden compared to tramadol monotherapy at higher doses, and its well-established position in the WHO pain ladder as a Step 2 analgesic. WHO-GMP certified facilities manufacture this combination for PCD pharma franchise companies and third party manufacturing arrangements. The consistent demand across hospital, retail, and institutional channels makes it a core product for any analgesic product portfolio. Indian manufacturers export tramadol-paracetamol tablets to regulated markets across Asia, Africa, and the Middle East.